Press Releases Roche Holding AG Swiss Exchange

Stocks

Market Closed - Swiss Exchange Other stock markets 23:30:07 09/06/2026 HKT			5-day change	1st Jan Change
318.80 ^CHF	-1.21%		+1.67%	-2.86%

08:49am	Samsung Elec invests $175 million to become top shareholder in US genetics firm	RE
06-10	Health Care Up Amid Multibillion Dollar Oncology Deals - Health Care Roundup	DJ

06-04	Roche rapidly develops a PCR test for Ebola within six days as rare Bundibugyo virus drives urgent need for detection	PR
06-02	FDA Accepts New Drug Application for Genentech’s Giredestrant in ER-Positive Early-Stage Breast Cancer, the First and Only Oral SERD With Positive Phase III Results in the Curative Setting	BU
06-01	Genentech to Present New Data Advancing Its Obesity Portfolio at the American Diabetes Association’s 2026 Scientific Sessions	BU
05-19	Genentech to Present New Data at ASCO 2026, Reinforcing Giredestrant's Potential to Transform the Treatment Paradigm in Early Breast Cancer	BU
05-16	FDA Approves Genentech’s Tecentriq for Adjuvant Muscle-Invasive Bladder Cancer With ctDNA-Guided Treatment	BU
04-30	Genentech to Present Extensive Data Showcasing Its Industry-Leading Ophthalmology Portfolio at ARVO 2026	BU
04-24	Genentech Partners With Comedy Icon Damon Wayans and diaTribe to Address Diabetes-Related Vision Loss With ‘All Eyes on DME’ Campaign	BU
04-22	Roche's ENSPRYNG (satralizumab) reduces risk of relapses by 68% demonstrating potential to become first treatment for MOGAD	AQ
04-22	Genentech’s Fenebrutinib Significantly Reduced Relapses Versus Standard of Care to Approximately One Every 17 Years in RMS	BU
04-21	Genentech’s Enspryng (Satralizumab) Reduces Risk of Relapses by 68% Demonstrating Potential to Become First Treatment for MOGAD	BU
04-21	CORRECTING and REPLACING FDA Accepts Application for Genentech’s Gazyva for the Treatment of the Most Common Form of Lupus	BU